Amaxa® Human T Cell Nucleofector® Kit

For unstimulated Human T Cells

Small round lymphoblastoid cells; subpopulation of human peripheral blood mononuclear cells (PBMC). PBMC should be purified from fresh human blood samples treated with an anti-coagulant or from leukocyte-enriched buffy coat

Example for Nucleofection® of CD3+ T cells with different reporter genes

PBMC were freshly isolated from buffy coat and transfected with Nucleofector® Program V-024 and pmaxGFP® Vector. 24 hours post Nucleofection®, cells were analyzed by flow cytometry. Lymphocytes were gated according to forward/side scatter (A). T cells were stained with antibody directed against CD3. Dead cells were excluded by propidium iodide staining and gating (B/C). maxGFP® Protein expression of T cells is shown after Nucleofection® without (D) and with plasmid DNA (E).

Transfection efficiency of human T cells 24 hours post Nucleofection®.
Cells were transfected with program U-014 or V-024 and 2 µg pmaxGFP® Vector. Cell viability (% PI negative) is usually 80% for both programs. However, the absolute number of viable cells is reduced with program V-024.

Luciferase expression of purified human T cells. Human T cells were purified by MACS separation. Purified T cells were transfected with the Human T Cell Nucleofector® Kit, program U-014 or program V-024 and 2 µg of a pG3-CMV plasmid. Luciferase expression was analyzed 4 hours, 24 hours and 48 hours after Nucleofection® and RLU were normalized to 1000 cells.

Product Description

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>VPA-1002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size (reactions)</td>
<td>25</td>
</tr>
<tr>
<td>Human T Cell Nucleofector® Solution</td>
<td>2.25 ml [2.05 ml + 10% overfill]</td>
</tr>
<tr>
<td>Supplement</td>
<td>0.5 ml [0.45 ml + 10% overfill]</td>
</tr>
<tr>
<td>pmaxGFP® Vector (0.5 µg/µl in 10 mM Tris pH 8.0)</td>
<td>30 µg</td>
</tr>
<tr>
<td>Certified cuvettes</td>
<td>25</td>
</tr>
<tr>
<td>Plastic pipettes</td>
<td>25</td>
</tr>
</tbody>
</table>

Storage and stability
Store Nucleofector® Solution, Supplement and pmaxGFP® Vector at 4°C. For long-term storage, pmaxGFP® Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector® Supplement is added to the Nucleofector® Solution it is stable for three months at 4°C.
**Required Material**

**Note** Please make sure that the entire supplement is added to the Nucleofector® Solution. The ratio of Nucleofector® Solution to supplement is 4.5 : 1. For a single reaction use 82 µl of Nucleofector® Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector® Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260 : A280 ratio should be at least 1.8
- 12-well culture plate or 6-well culture plate for coating (see below) or culture system of your choice
- **Culture medium:** Clonetics® Lymphocyte Growth Media-3 LGM-3® for serum-free culture [Lonza, Cat. No. CC-3211] or BioWhittaker® IMDM media for addition of 10% serum [Lonza, Cat.No. BE12-722F]
- **For isolation:** Ficoll-Paque™ Plus [GE Healthcare; Cat. No. 17-1440-03]; PBS containing 0.5% [w/v] BSA (PBS/BSA)
- **For enrichment (optional):** Pan T Cell Isolation Kit II [Miltenyi Biotec; Cat. No. 130-091-156] or RosetteSep™ Isolation Kit for human T cells [StemCell Technologies, Cat. No 15021]
- **For coating of plates (for post Nucleofection® stimulation):** Anti-Human CD3 MAB [OKt 3; eBioscience, Cat. No. 14-0037-82] and Anti-Human CD28 MAB [5E8; Research Diagnostics Inc., Cat. No. 10R-CD28bHUµg/µl]; control antibody [purified mIgG(K); BD-Pharmingen, Cat. No. 554 721]; antibodies should be diluted in carbonate buffer (32 mM Na₂CO₃/16 mM NaHCO₃) from 100 ng/µl stock solutions directly before use; Immuno™ Plate C96 Maxi Sorp™ [Nunc, Cat. No.: 430 341]
- Prewarm appropriate volume of culture medium to 37°C (2 ml per sample)
- Appropriate number of cells (5 – 10 x 10⁶ cells per sample; minimal cell number: 7 x 10⁵ cells, a lower cell number may lead to a major decrease of cell viability; maximal cell number: 2 x 10⁷ cells)

### 1. Pre Nucleofection®

**Notes**

- This protocol is designed for fresh unstimulated primary human T cells from whole PBMCs. Depending on application T cells can be further enriched (see below)
- Transfection results may be donor-dependent. For preparation, do not perform protocols using hypo-osmolar buffers. This may lead to high cell mortality after Nucleofection®
- For freshly isolated cells no cultivation is required prior to Nucleofection®
- For cryopreserved cells we recommend incubating the thawed cells for 1 – 2 hours at 37°C in culture medium before Nucleofection®
- For Nucleofection® of stimulated T cells, please refer to the Optimized Protocol for stimulated Human T Cells

**Coating of culture plates (optional for stimulation post Nucleofection®)**

1.1 Incubate each well with 1 ml (for 6-well) or 50 µl (for 96-well; Nunc Immuno™ Plate C96 Maxi Sorp™) of a solution of Anti-Human CD3 MAB at a final concentration of 1 µg/ml and Anti-Human CD28 MAB at a final concentration of 2 µg/ml (or with a solution of a control antibody [purified mIgG(K)] at a final concentration 3 µg/ml) at 37°C/5% CO₂ for 5 hours
1.2 Wash the wells carefully three times with PBS/BSA
Blood samples

1.3 Fresh human blood treated with an anticoagulant (e.g. heparin, citrate, ACD-A) or alternatively, leukocyte-enriched buffy coat not older than 8 hours. The samples should be diluted with 2 – 4 volumes of PBS containing 0.5% BSA (PBS/BSA)

Preparation of PBMC

1.4 Pipet 15 ml Ficoll-Paque™Plus in a 50 ml conical tube
1.5 Overlay Ficoll-Paque™Plus with 35 ml blood sample and centrifuge at 750xg for 20 minutes at 20°C in a swinging-bucket rotor without brake
1.6 Remove the upper layer leaving the mononuclear cell layer undisturbed at the interphase. Carefully transfer the interphase cells (lymphocytes and monocytes) to a new 50 ml conical tube
1.7 Add PBS/BSA to 50 ml, mix and centrifuge at 350xg for 10 minutes at 4°C. Remove the supernatant carefully
1.8 Resuspend the cell pellet in 25 ml of PBS/BSA and centrifuge at 160xg for 15 minutes at 4°C. Remove the supernatant carefully
1.9 Resuspend the cell pellet in 25 ml PBS/BSA and centrifuge at 300xg for 10 minutes at 4°C. Remove the supernatant carefully
1.10 Resuspend cell pellet in 5 ml PBS/BSA and count the cells

Note Purified PBMC may be stored at 4°C overnight in PBS/BSA, but this can cause a significant loss of transfection efficiency.

Enrichment of T cells (optional)

1.11 Primary human T cells can be further enriched by using Pan T Cell Isolation Kit II [Miltenyi] or RosetteSep™ Isolation Kit for human T cells [StemCell Technologies] according to the manufacturer’s protocol
## 2. Nucleofection®

One Nucleofection® Sample contains

| 5 – 10 x 10⁶ cells | 1 – 5 µg plasmid DNA (in 1 – 5 µl H₂O or TE) or 2 µg pmaxGFP® Vector or 30 – 300 nM siRNA (3 – 30 pmol/sample) | 100 µl Human T Cell Nucleofector® Solution |

2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution

2.2 Prepare 12-well plates by filling appropriate number of wells with 2 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator for at least 30 minutes

2.3 Count the cells and determine cell density

2.4 Centrifuge the required numbers of cells (5 – 10 x 10⁶ cells per sample) at 200g for 10 minutes at room temperature. Discard supernatant completely so that no residual PBS/BSA covers the cell pellet

2.5 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector® Solution per sample. Avoid storing the cell suspension longer than 20 minutes in Human T Cell Nucleofector® Solution, as this reduces cell viability and gene transfer efficiency

2.6 Combine 100 µl of cell suspension with 1 – 5 µg DNA, 2 µg pmaxGFP® Vector or 30 nM – 300 nM siRNA (3 – 30 pmol/sample) or other substrates

2.7 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap

2.8 Select the appropriate Nucleofector® Program U-014 for high viability (e.g., T cells that should be stimulated post Nucleofection®) or V-024 for high expression level (U-14 or V24 for Nucleofector® I Device)

2.9 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program

2.10 Take the cuvette out of the holder once the program is finished

2.11 Add ~500 µl of the pre-equilibrated culture media to the cuvette and gently transfer the sample into the 12-well plate (final volume of 2 ml media per well/sample). Use the supplied pipettes and avoid repeated aspiration of the sample

## 3. Post Nucleofection®

3.1 Incubate the cells in a humidified 37°C/5% CO₂ incubator until analysis. Gene expression is often detectable after only 4 – 8 hours

3.2 Unstimulated T cells can be cultured up to 48 hours. Medium change 6 hours post Nucleofection® leads to an increased viability after transfection. Spin the culture dishes for 8 minutes at 140xg in a tissue culture centrifuge. Carefully remove the medium and add fresh pre-equilibrated culture medium. Alternatively once replace half of the medium with fresh medium during the cultivation time

3.3 Stimulation (optional): Please do not add stimuli immediately after Nucleofection® as this may lead to increased cell mortality. For stimulation by antiCD3/antiCD28, transfer cells to an antibody coated plate (see chapter 1) containing fresh medium 5 hours post Nucleofection®, and incubate cells for another 43 hours. Alternatively you may add fresh medium containing IL-2 or other suitable stimuli 4 – 12 hours post Nucleofection®
Additional Information

For an up-to-date list of all Nucleofector® References, please refer to:
www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA / Canada
Phone: 800 521 0390 (toll-free)
Fax: 301 845 8338
E-mail: scientific.support@lonza.com

Europe and Rest of World
Phone: +49 221 99199 400
Fax: +49 221 99199 499
E-mail: scientific.support.eu@lonza.com

Lonza Cologne AG
50829 Cologne, Germany

Please note that the Amaxa® Nucleofector® Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.
The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.
Amaxa, Nucleofector, Nucleofection, maxGFP, LGM-3, Clonetics and Biowhitaker are registered trademarks of the Lonza Group or its affiliates.
Other product and company names mentioned herein are the trademarks of their respective owners.
This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited.
USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.
The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.
The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.
No statement is intended or should be construed as a recommendation to infringe any existing patent.
© Copyright 2009, Lonza Cologne AG. All rights reserved DPA-1002 08/09